BD Posts Q4 Revenue of $5.3B, Guides FY27 Adjusted EPS to $13.10-$13.30
BDX sits 60% above its 52-week low of $127.536 on elevated volume (2.6× avg).
Summary
BD reported Q4 revenue of $5.3 billion (+5.4%) and adjusted EPS of $4.15, with FY26 free cash flow up 42.5% to $2.9 billion. FY27 guidance calls for low single-digit revenue growth and adjusted EPS of $13.10 to $13.30.
Key Events · Earnings and Guidance · BDX
-
Q4 Revenue Grows 5.4% to $5.3B
Fourth-quarter revenue came in at $5,274 million versus $5,005 million a year earlier, up 5.4% as reported and 5.6% FXN; Interventional led segments at 7.6% growth.
-
FY27 Adjusted EPS Guided to $13.10-$13.30
Off FY26 adjusted diluted EPS of $12.70, the guide implies +3.1% to +4.7%; revenue growth is guided to low single digits on both a reported and FXN basis.
-
Free Cash Flow Jumps 42.5% to $2.9B
Cash from continuing operations rose 30.0% to $3,605 million and free cash flow reached $2,933 million, supporting $2,433 million of share repurchases and $1,161 million of dividends paid in FY26.
-
Tariff Relief Tied to $19B U.S. Investment
The U.S. government partnership commits $19 billion of investment over several years, including $3 billion for manufacturing expansion, in exchange for relief from future Section 232 tariffs subject to milestones.
Analysis · BDX · Industrial Applications And Services
BD closed its first full year as a focused MedTech company with fourth-quarter revenue up 5.4% to $5.3 billion and adjusted diluted EPS of $4.15, a 27.3% increase. Full-year free cash flow rose 42.5% to $2.9 billion, funding the buyback and debt paydown that followed the February spin-off of the Biosciences and Diagnostics business. The FY27 adjusted EPS guide of $13.10 to $13.30 implies only about 3.1% to 4.7% growth off FY26's $12.70, and revenue growth is guided to low single digits — a modest step-down that matters with the stock near its 52-week high. The $19 billion U.S. manufacturing commitment, including $3 billion for plant expansion, is the swing factor: it buys relief from future Section 232 tariffs on covered products, but only if BD hits agreed milestones.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDX was trading at $204.07 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $57B. The 52-week trading range was $127.54 to $209.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.